



SPECIES DESIGNATION AND MIC DETERMINATION

EXTERNAL QUALITY ASSESSMENT SCHEME ON ANTIMICROBIAL SUSCEPTIBILITY TESTING 2020

CHU PELLEGRIN CNR CAMPYLOBACTERS-HELICOBACTERS FRANCE

Dear Participant

In this evaluation report your individual results are presented for the sixth external quality assessment on antimicrobial susceptibility testing (EQA6-AST) for national public health laboratories for *Salmonella* and *Campylobacter* in the Food-and Waterborne Diseases and Zoonoses Network (FWD-Net). The EQA was organised by Statens Serum Institut (SSI) in 2020.

Enclosed with this document are 6 pages including the EUCAST ECOFFs and clinical breakpoints for *Campylobacter*, your own submitted results, expected results established by the EQA provider and a comparison of these. Submitted gradient strip results were transformed in a log_2 base scale in order to compare to micro-broth dilutions. Please study the results carefully and do not hesitate to contact us if you have any questions or suggestions.

Thank you very much for your participation.

Yours sincerely,

EQA team Denmark





SPECIES DESIGNATION AND MIC DETERMINATION

EUCAST ECOFFs and clinical breakpoints used for *Campylobacter*

| | r | MIC determin | nation (μg/m | L) | L) Disk Dif | | | fusion (mm) | | |
|-----------------------|-------|--------------|--------------|----------|-------------|---------|-----------------|-------------|--|--|
| | | | EUCAST | clinical | | | EUCAST Clinical | | | |
| Antimicrobial agent | EUCAS | T ECOFF | break | point | EUCAS | T ECOFF | breakpoint | | | |
| Mandatory | WT≤ | NWT > | S≤ | R > | WT≥ | NWT < | S≥ | R < | | |
| Ciprofloxacin | 0.5 | 0.5 | 0.5 | 0.5 | 26 | 26 | 26 | 26 | | |
| Erythromycin (jejuni) | 4 | 4 | 4 | 4 | 22 | 22 | 20 | 20 | | |
| Erythromycin (coli) | 8 | 8 | 8 | 8 | 24 | 24 | 24 | 24 | | |
| Tetracycline (jejuni) | 1 | 1 | 2 | 2 | 30 | 30 | 30 | 30 | | |
| Tetracycline (coli) | 2 | 2 | 2 | 2 | 30 | 30 | 30 | 30 | | |
| Optional | onal | | | | | | | | | |
| Gentamicin (jejuni) | 2 | 2 2 | | | 20 | 20 | | | | |
| Gentamicin (coli) | 2 | 2 | | | | | | | | |





SPECIES DESIGNATION AND MIC DETERMINATION

Strain EQA_AST.C20.0001

Species designation

| Expected result | Your reported result | In accordance with expected |
|-----------------|----------------------|-----------------------------|
| C. coli | C. coli | Correct |

Antimicrobial susceptibility testing

| Antimicrobial agents | | Exp | pected results as esta EQA provide | • | | | Your reported re | esults and interpreta | ation | |
|----------------------|------------|-----|---|--|------|---------------|---|--|---|---------------------------|
| Mandatory | Val (mg | | Interpretation based on EUCAST ECOFFs | Interpretation based on Clinical breakpoints | _ | alue g/L)¹ | Value in accordance with expected (+/- 1 dilution difference) ² | Interpretation based on EUCAST ECOFFs ³ | Interpretation in accordance with expected ⁴ | Reported genotypic result |
| Ciprofloxacin | = | 16 | NWT | R | >32 | (32) | Incorrect | NWT | Correct | - |
| Erythromycin | = | 64 | NWT | R | >256 | (256) | Incorrect | NWT | Correct | - |
| Tetracycline | = | 64 | NWT | R | >256 | (256) | Incorrect | NWT | Correct | - |
| Optional | | | | | | | | | | |
| Gentamicin | > | 16 | NWT | NA | >256 | (256) | Correct | NWT | Correct | - |

| EQA provider's feedback (if relevant) | |
|---------------------------------------|--|
| | |

¹Log transformed values are shown in brackets.

² Performance evaluated as correct if the reported MIC value was within +/-1 dilution from the expected MIC established by the EQA provider.

³ Value reported by participant interpreted by EQA provider based on EUCAST ECOFFs (EUCAST clinical breakpoint used when no EUCAST ECOFF available).

⁴ Value reported by participant interpreted by EQA provider based on EUCAST ECOFFs compared to the expected interpretation as established by EQA provider.





SPECIES DESIGNATION AND MIC DETERMINATION

Strain EQA_AST.C20.0002

Species designation

| Expected result | Your reported result | In accordance with expected |
|-----------------|----------------------|-----------------------------|
| C. jejuni | C. jejuni | Correct |

Antimicrobial susceptibility testing

| Antimicrobial agents | | | | | | | Your reported res | ults and interpretati | on | |
|----------------------|----|---|----|--|--|--|---------------------------------|-----------------------|---------|---|
| Mandatory | | Value based on EUCAST based on Clinical Value (mg/L) ECOFFs breakpoints (mg/L) ¹ | | Value in accordance with expected (+/- 1 dilution difference) ² | Interpretation based on EUCAST ECOFFs ³ | Interpretation in accordance with expected ⁴ | Reported genotypic result | | | |
| Ciprofloxacin | <= | 0,12 | WT | S | =0,094 | (0,125) | Correct | WT | Correct | - |
| Erythromycin | <= | 1 | WT | S | =0,5 | (0,5) | Correct | WT | Correct | - |
| Tetracycline | <= | 0,5 | WT | S | =0,064 | (0,0625) | Correct | WT | Correct | - |
| Optional | | | | | | | | | | |
| Gentamicin | = | 0,5 | WT | NA | =0,125 | (0,125) | Incorrect | WT | Correct | - |

| EQA provider's feedback (if relevant) | |
|---------------------------------------|--|
| | |

¹Log transformed values are shown in brackets.

² Performance evaluated as correct if the reported MIC value was within +/-1 dilution from the expected MIC established by the EQA provider.

³ Value reported by participant interpreted by EQA provider based on EUCAST ECOFFs (EUCAST clinical breakpoint used when no EUCAST ECOFF available).

⁴ Value reported by participant interpreted by EQA provider based on EUCAST ECOFFs compared to the expected interpretation as established by EQA provider.





SPECIES DESIGNATION AND MIC DETERMINATION

Strain EQA_AST.C20.0003

Species designation

| Expected result | Your reported result | In accordance with expected |
|-----------------|----------------------|-----------------------------|
| C. coli | C. coli | Correct |

Antimicrobial susceptibility testing

| Antimicrobial agents | Expected results as established by EQA provider | | | | | Your reported results and interpretation | | | | | | |
|----------------------|---|----------------|---|--|-------|--|---|--|--|---------------------------------|--|--|
| Mandatory | | /alue mg/L) | Interpretation based on EUCAST ECOFFs | Interpretation based on Clinical breakpoints | | Value (mg/L)¹ | Value in accordance with expected (+/- 1 dilution difference) ² | Interpretation based on EUCAST ECOFFs ³ | Interpretation in accordance with expected ⁴ | Reported genotypic result | | |
| Ciprofloxacin | = | 4 | NWT | R | =3 | (4) | Correct | NWT | Correct | - | | |
| Erythromycin | > | 128 | NWT | R | >256 | (256) | Correct | NWT | Correct | - | | |
| Tetracycline | = | 2 | WT | S | =3 | (4) | Correct | NWT | Incorrect | - | | |
| Optional | | | | | | | | | | | | |
| Gentamicin | = | 1 | WT | NA | =0,25 | (0,25) | Incorrect | WT | Correct | - | | |

| EQA provider's feedback (if relevant) | |
|---------------------------------------|--|
| | |

¹Log transformed values are shown in brackets.

² Performance evaluated as correct if the reported MIC value was within +/-1 dilution from the expected MIC established by the EQA provider.

³ Value reported by participant interpreted by EQA provider based on EUCAST ECOFFs (EUCAST clinical breakpoint used when no EUCAST ECOFF available).

⁴ Value reported by participant interpreted by EQA provider based on EUCAST ECOFFs compared to the expected interpretation as established by EQA provider.





SPECIES DESIGNATION AND MIC DETERMINATION

Strain EQA_AST.C20.0004

Species designation

| Expected result | Your reported result | In accordance with expected |
|-----------------|----------------------|-----------------------------|
| C. coli | C. coli | Correct |

Antimicrobial susceptibility testing

| Antimicrobial agents | Expected results as established by EQA provider | | | | | | Your reported resu | lts and interpretation | on | |
|----------------------|---|-----|--------------------------------------|----|---|--|--|---------------------------------|---------|---|
| Mandatory | Value based on based on Clinical (mg/L) EUCAST ECOFFs breakpoints | | Value with (mg/L) ¹ (+/-: | | Value in accordance with expected (+/- 1 dilution difference) ² | Interpretation based on EUCAST ECOFFs ³ | Interpretation in accordance with expected ⁴ | Reported genotypic result | | |
| Ciprofloxacin | = | 16 | NWT | R | >32 | (32) | Incorrect | NWT | Correct | - |
| Erythromycin | > | 128 | NWT | R | >256 | (256) | Correct | NWT | Correct | - |
| Tetracycline | > | 64 | NWT | R | >256 | (256) | Correct | NWT | Correct | - |
| Optional | | | | | | | | | | |
| Gentamicin | = | 0,5 | WT | NA | =0,25 | (0,25) | Correct | WT | Correct | - |

| EQA provider's feedback (if relevant) | |
|---------------------------------------|--|
| | |

¹Log transformed values are shown in brackets.

² Performance evaluated as correct if the reported MIC value was within +/-1 dilution from the expected MIC established by the EQA provider.

³ Value reported by participant interpreted by EQA provider based on EUCAST ECOFFs (EUCAST clinical breakpoint used when no EUCAST ECOFF available).

⁴ Value reported by participant interpreted by EQA provider based on EUCAST ECOFFs compared to the expected interpretation as established by EQA provider.





SPECIES DESIGNATION AND MIC DETERMINATION

Strain EQA_AST.C20.0005

Species designation

| Expected result | Your reported result | In accordance with expected |
|-----------------|----------------------|-----------------------------|
| C. jejuni | C. jejuni | Correct |

Antimicrobial susceptibility testing

| Antimicrobial agents | Expected results as established by EQA provider | | | Your reported results and interpretation | | | | | | |
|----------------------|---|----------------|---|--|------------------------------|---------|--|--|--|---------------------------------|
| Mandatory | | /alue mg/L) | Interpretation based on EUCAST ECOFFs | Interpretation based on Clinical breakpoints | Value (mg/L) ¹ | | Value in accordance with expected (+/- 1 dilution difference) ² | Interpretation based on EUCAST ECOFFs ³ | Interpretation in accordance with expected ⁴ | Reported genotypic result |
| Ciprofloxacin | <= | 0,12 | WT | S | =0,094 | (0,125) | Correct | WT | Correct | - |
| Erythromycin | <= | 1 | WT | S | =0,5 | (0,5) | Correct | WT | Correct | - |
| Tetracycline | = | 64 | NWT | R | >256 | (256) | Incorrect | NWT | Correct | - |
| Optional | | | | | | | | | | |
| Gentamicin | = | 0,5 | WT | NA | =0,19 | (0,25) | Correct | WT | Correct | - |

| EQA provider's feedback (if relevant) | | |
|---------------------------------------|--|--|
| | | |

¹Log transformed values are shown in brackets.

² Performance evaluated as correct if the reported MIC value was within +/-1 dilution from the expected MIC established by the EQA provider.

³ Value reported by participant interpreted by EQA provider based on EUCAST ECOFFs (EUCAST clinical breakpoint used when no EUCAST ECOFF available).

⁴ Value reported by participant interpreted by EQA provider based on EUCAST ECOFFs compared to the expected interpretation as established by EQA provider.